I added 4000 shares after hours. Just a modest but sustained improvement is HUGE. The health care savings would be tremendous. Many successful drugs are only incremental improvements, but reap billions in sales.
I bought 4K shares AH on Friday because of the news. The potential is incredible as stem cell therapy has only been tried in less than optimum cases and has worked. Getting off a respirator is huge and saves big money in hospital costs. As stem cells are implanted in better candidates the results should be even better. The potential worldwide market is huge!
The hatchet piece in San Francisco Business News conveniently ignores the fact that two major pharmas thought enough of XOMA compounds to do deals. It s just a matter of time before XOMA sells Gevo and/or is bought out.
The recent heavy options buying of Feb 18 $1.00 Calls virtually guaranteed that the manipulators would keep the Calls out of the money. Monday should see a nice rebound.
1) Their in-house programs;
2) Partnership with Novo Nordisk
3) Partnership with Novartis;
4) Holds $1,000,000 in Agenus (AGEN) stock
Sentiment: Strong Buy
The large AH block trades are either dark pool trades that have a time lag in getting reported or order imbalances that get settled.
(Today's bear raid creates a great entry point. No chance of a R/S as annual meeting filings do not mention and XOMA can easily transfer to NASDAQ Capital Market without being over one dollar).
"The current technical condition for XOMA is strong and the chart pattern suggests that upward momentum should continue.
The stock has outperformed the market over the last 50 trading days when compared to the S&P 500. The MACD-LT is confirming that the
intermediate-term trend is bullish. Upside momentum, as measured by the 9-day RSI indicator is very strong. Over the last 50 trading sessions, there
has been more volume on up days than on down days indicating that XOMA is under accumulation, which is a bullish condition. The stock is trading
above a rising 50-day moving average. This validates the strong technical condition for XOMA."
XOMA has a track record of getting deals done: Agenus, Novo Nordsk, Novartis.
(From XOMA website)
"Given XOMA’s focus on endocrinology, we have decided to stop all gevokizumab related development activities and is initiating a formal sales process for the asset. As a result, the Company is closing the Phase 3 program in patients suffering from pyoderma gangrenosum. A preliminary review of the data from the approximate 25 patients enrolled in the trial to date did not show a clear signal of activity in this indication. XOMA has been approached by several companies interested in gevokizumab and data from all gevokizumab studies will be available to potential buyers.
Notice XOMA says hat they have been approached by several companies. XOMA did no have to go out begging for companies to look at GEVO. Many many companies have staff actively pursuing so-called "failed" drugs. The blockbuster Viagra was an accidental winner for Pfizer: the original studies never even considered sexual disfunction.
NO ONE knows what GEVO can still produce. A reading of the company website says it has licensed its technology to 60, count 'em, 60 companies. The law of averages are on our side.
Xoma's library is a huge asset and more deals could be on the way. When a company has imminent news or important discussions an earnings conference call is usually omitted.